SurModics to Webcast Annual Meeting January 28

January 14, 2008 at 4:24 PM EST
Special Guest from Genzyme Pharmaceuticals to Present
EDEN PRAIRIE, Minn., Jan 14, 2008 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Monday, January 28, at 4:00 p.m. CT.

Bruce Barclay, president and chief executive officer, Phil Ankeny, senior vice president and chief financial officer, and Ken Melrose, chairman of the board, will discuss financial results and achievements for the fiscal year ended September 30, 2007 as well as results from the first quarter of fiscal year 2008, and speak about the company's strategy and prospects.

In addition, as special guest, SurModics is pleased to welcome Daniel O. Hayden, senior vice president and general manager for Genzyme Pharmaceuticals, who will present an overview of Genzyme corporation, including the Pharmaceuticals division, as well as discuss the strategic collaboration with Brookwood Pharmaceuticals, a recently acquired subsidiary of SurModics. Also presenting will be Arthur J. Tipton, Ph.D., vice president of SurModics and president of Brookwood Pharmaceuticals.

To access the webcast, go to the investor relations portion of the company's website at, on the day of the Annual Meeting and click on the webcast icon. In addition, the Annual Meeting audio and slide presentation will be archived on the company's website following the meeting.

About SurModics, Inc.

SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site-specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics' Bravo(TM) drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products. SurModics is headquartered in Eden Prairie, MN. More information about the company can be found at The content of SurModics' website is not part of this release or part of any filings the company makes with the SEC.

SOURCE: SurModics, Inc.

SurModics, Inc.
Maggie Knack, Director, Investor Relations